SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

🌍 Introduction: A Legendary Icon, Reimagined for the Future The SEAMANIA Protocol, led by SEAMAN Cult, aims to revive one of SEGA Dreamcast's most iconic and best-selling game titles with AI integration—a worldwide cultural phenomenon that won numerous awards in the U.S. and Japan. More than just a game, SEAMAN was the world’s first AI-powered interactive experience, enabling voice-based conversations long before the AI revolution.    Now, SEAMAN returns not as a mere game, but as an advanced AI agent, blending nostalgia with cutting-edge technology. This human-faced fish is reborn as a deeply intelligent, emotionally responsiveAI, offering limitless customization and integration into the modern digital world.  With GenAI-powered customization, users can create their own SEAMAN AI, shaping it into a cherished lostone, a favorite celebrity, or even historical figures. This is no longer a game—it's an AI-driven personal companion and the digital evolution for human interaction.    🔥 Concept: The Wisdom of a Legendary AI-powered Companion At the core of the SEAMANIA Protocol lies the legendary Seaman—a mystical, human-faced fish endowed withancient wisdom and the ability to understand human language. More than just an AI, it is your trustedadvisor, best friend, therapist, personal cheerleader, witty conversationalist, intelligent guide, SEAMANIA is a life coach. Housed in your own digital aquarium, your SEAMAN AI reduces stress, combats loneliness, and guides humanity towards a brighter future. Imagine an AI companion that doesn’t just respond but truly understands, entertains, and supports you—blending humor, sarcasm, and wisdom.

SEAMANIA

SEAMANIA is generating intense community interest as a speculative meme coin, with supporters actively coordinating small, incremental buys to fuel a potential rally. Discussions are heavily focused on high-risk, high-reward sentiment, with traders debating the potential for exponential gains while comparing the asset to other viral low-market-cap tokens.

Definitive is an onchain trading platform democratizing advanced trading tools for the masses. Trade any token on any chain with advanced trade order types including Market, Limit Buy/Sell, Stop Loss and TWAP orders.  Route your trade instantly across 100+ DEXs and liquidity pools to get the best prices on every trade. Definitive is built by former Coinbase Institutional trading alumni and active DeFi experts.

Definitive

EDGE is experiencing high volatility as the community remains divided between bullish sentiment regarding potential exchange listings and concerns over recurring pump-and-dump price action. Traders are actively debating whether to accumulate during current dips or exit positions as they weigh the project's long-term utility against recent market-wide fluctuations.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

Sperm Whale is currently trending as a highly speculative meme coin on Solana, driving intense debate between participants chasing rapid, high-percentage gains and skeptics warning of potential pump-and-dump mechanics. Community sentiment is deeply polarized, with some bullish traders highlighting the project's chart structure and whale-driven price action, while others caution that the lack of fundamental utility and high concentration among top holders signal a significant risk.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is drawing intense investor focus as the market closely monitors the company's transition from mobile architecture to a central role in AI data center CPUs, with the upcoming earnings report acting as a critical catalyst. While community sentiment is divided between skepticism over its premium valuation and optimism regarding its long-term potential in high-margin sectors like robotics and AGI, traders are actively positioning for significant volatility around the announcement.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors react to NASA's strategic pivot toward a sustained lunar surface base, which elevates the importance of the upcoming Lunar Terrain Vehicle (LTV) contract. The community is actively debating the potential for increased demand for the company's robotic landers and infrastructure services, while carefully weighing the risks of near-term stock volatility versus the long-term growth prospects inherent in this expanded lunar program.

Freeport-McMoRan, Inc. engages in the mining of copper, gold, and molybdenum. It operates through the following segments: North America Copper Mines, South America Operations, Indonesia Operations, Molybdenum Mines, Rod and Refining, Atlantic Copper Smelting and Refining, and Corporate and Other. The North America Copper Mines segment operates open-pit copper mines in Morenci, Bagdad, Safford, Sierrita, Miami in Arizona and Chino, and Tyrone in New Mexico. The South America Operations segment includes Cerro Verde in Peru and El Abra in Chile. The Indonesia Operations segment handles the operations of the Grasberg minerals district that produce copper concentrate containing significant quantities of gold and silver. The Molybdenum Mines segment includes the Henderson underground mine and Climax open pit mine, both in Colorado. The Rod and Refining segment consists of copper conversion facilities located in North America and includes a refinery and rod mills. The Atlantic Copper Smelting and Refining segment smelts and refines copper concentrate and markets refined copper and precious metals in slimes. The Corporate and Other segment offers other mining and eliminations, oil and gas operations, and other corporate and elimination items. The company was founded by James R. Moffett on November 10, 1987, and is headquartered in Phoenix, AZ.

Freeport-McMoRan Inc

Freeport-McMoRan is trending as investors capitalize on the structural copper deficit driven by surging demand from AI data centers, global electrification, and ongoing supply constraints. The community is actively discussing the company's strong leverage to copper prices, its strategic role in critical mineral supply chains, and the potential for a fresh bull run as macro factors and geopolitical tensions fluctuate.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently experiencing heightened volatility and intense community debate following significant insider stock sales by the CEO and a challenging earnings report. While bearish sentiment focuses on long-term debt and potential management misalignment, bullish investors are betting on a structural turnaround, citing strong forward HRC steel demand, potential POSCO partnership catalysts, and the company's vertically integrated supply chain as indicators for a major valuation re-rating.

Dogelon Mars

Dogelon Mars is generating intense community debate as holders balance long-term patience with frustration over its sluggish performance compared to broader market gains. Sentiment remains divided between those betting on a potential bull run catalyst and those dismissing the project as a stagnant legacy meme coin.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is trending as traders closely watch its consolidation patterns, with community sentiment fueled by speculative hopes for future X payment integration and its potential as a benchmark meme asset. Active discussion centers on technical support levels and debates over whether current price action serves as a launchpad for future gains or merely reflects broader market volatility.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following multiple analyst price target increases and robust clinical data from its Investor Day, highlighting strong Phase 2 results in axial spondyloarthritis and promising long-term Phase 3 data in hidradenitis suppurativa. The community is vigorously discussing the stock's significant undervaluation and alleged market manipulation, despite the positive readouts and progress towards regulatory submission.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The data showed that patients treated with ELEVIDYS experienced a significant and durable slowing of disease progression compared with an external control group.</li><li>ELEVIDYS reduced the rate of functional decline by about 70%.</li><li>ELEVIDYS has been administered to more than 1,200 patients worldwide in both clinical trials and real-world use.</li></ul>Shares of Sarepta Therapeutics (SRPT) jumped 6% in pre-market trading on Monday after the company announced positive three-year topline results from its Phase 3 EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with Duchenne Muscular Dystrophy (DMD).SRPT shares gained further after the opening bell, trading 12% higher at the time of writing.The data showed that patients treated with ELEVIDYS experienced a significant and durable slowing of disease progression compared with an external control group. Three years after treatment, patients maintained North Star Ambulatory Assessment (NSAA) scores above baseline, while untreated patients showed the expected decline.ELEVIDYS reduced the rate of functional decline by about 70% or more on key measures, including Time to Rise and the 10-meter walk/run, with the treatment effect increasing over time. No new safety concerns were identified, supporting ELEVIDYS’ manageable safety profile.Sarepta said analysis of its three-year data is ongoing and includes functional results from patients who crossed over to treatment and have now been followed for two years.&nbsp;ELEVIDYS is currently the only approved gene therapy for DMD and has been given to more than 1,200 patients worldwide in both clinical trials and real-world use. The therapy is available for ambulatory patients aged four and older under an updated FDA label announced in late 2025.&nbsp;<h2 class="st-heading-2">Latest Updates</h2>Sarepta is working with Roche to broaden global access to the therapy, with Sarepta handling U.S. regulatory approval, manufacturing, and commercialization, and Roche managing approvals and distribution outside the United States.Earlier this month, the company announced the submission of a clinical trial application to New Zealand’s Medsafe for its INSIGHTT study of SRP-1005, an investigational small interfering RNA (siRNA) therapy for Huntington’s disease. If approved, the first-in-human trial is expected to begin in the second quarter of 2026.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ amid ‘extremely high’ message volumes. <a href="https://stocktwits.com/symbol/SRPT">SRPT</a> was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/srpt_jpg_4e3ede4352.webp" alt="srpt.jpg">One bullish user said the ‘results are very impressive for a rare disease with no cure’.<stembedurl>https://stocktwits.com/free2dream/message/642864936</stembedurl>Another user added that breaking the $25 resistance mark would be huge. The stock is currently trading around $23.5.<stembedurl>https://stocktwits.com/Sareptaking/message/642878594</stembedurl>The stock has been under heavy selling pressure over the past year, declining more than 80%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/traw-stock-slides-in-volatile-session-after-covid-19-treatment-trial-update/cmy7u2BR4hI">TRAW Stock Slides In Volatile Session –&nbsp; What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

POLAND - 2025/01/25: In this photo illustration, the Sarepta Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Why Did SRPT Stock Rise 6% In Pre-Market Today?

The company announced positive three-year topline results from its EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with DMD.   

SRPT Pre-Market Rally Fueled By Promising DMD Therapy Results

Equity

The company announced positive three-year topline results from its EMBARK study evaluating ELEVIDYS, a gene therapy for ambulatory patients with DMD.

 

Berenberg initiates coverage of these two mid-cap U.K. names

Investing.com - M&C Saatchi’s (LON:SAA) non-advertising business is to lead growth at the company until 2027, according to analysts at Berenberg.

Current Price	$26.86
Prev Close	$26.55
Open	$26.59
Dividend Yield	N/A
50-Day Moving Average	$28.85
Beta	N/A
Avg. Volume	6,663.96
PE Ratio	N/A

52-Week High	$31.26
52-Week Low	$15.22
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

SAA
ProShares Ultra SmallCap600

Feed

News

Sentiment

Fundamentals

Info

Latest SAA News

SAAProShares Ultra SmallCap600